Drug intelligence / Profile preview

FTX-6274

Development stage: Preclinical
Lead developer: Fulcrum Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

FTX-6274 is an oral small molecule inhibitor of embryonic ectoderm development (EED), a component of the polycomb repressive complex 2 (PRC2), under preclinical development by Fulcrum Therapeutics for the treatment of castration-resistant prostate cancer (CRPC). By inhibiting EED, FTX-6274 targets epigenetic regulation of gene expression, aiming to disrupt the PRC2-mediated chromatin modification that supports tumor progression in CRPC.

Targets

EED (Embryonic ectoderm development protein)

Beyond the preview

Go deeper on FTX-6274.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FTX-6274.

Explore the full profile